title: Adalimumab: a new modality for Behçet's disease?
authors.forename: J A M
authors.initials: JA
authors.lastname: van Laar
authors.forename: T
authors.initials: T
authors.lastname: Missotten
authors.forename: P L A
authors.initials: PL
authors.lastname: van Daele
authors.forename: A
authors.initials: A
authors.lastname: Jamnitski
authors.forename: G S
authors.initials: GS
authors.lastname: Baarsma
authors.forename: P M
authors.initials: PM
authors.lastname: van Hagen
mesh_terms: D000068879:Adalimumab; D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001528:Behcet Syndrome / Q000188:drug therapy*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D012189:Retrospective Studies; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab